Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases. [electronic resource]
Producer: 20150413Description: 1629-35 p. digitalISSN:- 1542-6270
- Animals
- Antibodies, Monoclonal, Humanized -- adverse effects
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Colitis, Ulcerative -- drug therapy
- Crohn Disease -- drug therapy
- Humans
- Inflammatory Bowel Diseases -- drug therapy
- Integrins -- antagonists & inhibitors
- Male
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.